TGF-β increases miR-182 levels in GBM, which further mediates NF-κB signaling pathway via targeting various negative regulators of NF-κB, such as TNF-α-induced protein 3-interacting protein 1 (TNIP1), optineurin (OPTN), ubiquitin specific peptidase 15 (USP15), and cylindromatosis (CYLD). Here, NFKB1 is linked to glioblastoma.